Physician profile
Joseph A Oommen
NPI 1770518516
$8,178.00
in general payments reported to CMS, 2019-2025
61 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,290 · 2020: $388 · 2021: $976 · 2022: $1,674 · 2023: $1,930 · 2024: $1,056 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.77 | 2021-2025 | |
| Acadia Pharmaceuticals INC | $957.40 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $504.17 | 2019-2025 | |
| Ucb, INC. | $427.37 | 2019-2024 | Briviact, Fintepla, Nayzilam |
| Pfizer INC. | $424.33 | 2023-2025 | |
| Biogen, INC. | $296.80 | 2019-2024 | Vumerity, Avonex, Tysabri |
| Neurelis, INC. | $288.62 | 2021-2023 | Valtoco |
| Emd Serono, INC. | $227.33 | 2019-2023 | Mavenclad |
| Boston Scientific Corporation | $208.26 | 2021-2023 | Vercise |
| Teva Pharmaceuticals USA, INC. | $200.17 | 2019-2024 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $174.92 | 2019-2025 | Ingrezza, Ongentys |
| Jazz Pharmaceuticals INC. | $161.91 | 2022-2024 | Epidiolex |
| Assertio Therapeutics, INC. | $144.99 | 2019-2020 | |
| Allergan, INC. | $143.35 | 2019-2021 | |
| Eisai INC. | $133.23 | 2019-2024 |
Show all 60 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Oommen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.